Targeted knockdown of IQGAP1 inhibits the progression of esophageal squamous cell carcinoma in vitro and in vivo

IQGAP1 is a scaffolding protein that can regulate several distinct signaling pathways. The accumulating evidence has demonstrated that IQGAP1 plays an important role in tumorigenesis and tumor progression. However, the function of IQGAP1 in esophageal squamous cell carcinoma (ESCC) has not been thor...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 9; no. 5; p. e96501
Main Authors Wang, Xiao-Xia, Wang, Kang, Li, Xiao-Zhong, Zhai, Li-Qin, Qu, Chong-Xiao, Zhao, Yan, Liu, Zhi-Rong, Wang, Hui-Zhen, An, Qi-Jun, Jing, Li-Wei, Wang, Xu-Hong
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 06.05.2014
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:IQGAP1 is a scaffolding protein that can regulate several distinct signaling pathways. The accumulating evidence has demonstrated that IQGAP1 plays an important role in tumorigenesis and tumor progression. However, the function of IQGAP1 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly investigated. In the present study, we showed that IQGAP1 was overexpressed in ESCC tumor tissues, and its overexpression was correlated with the invasion depth of ESCC. Importantly, by using RNA interference (RNAi) technology we successfully silenced IQGAP1 gene in two ESCC cell lines, EC9706 and KYSE150, and for the first time found that suppressing IQGAP1 expression not only obviously reduced the tumor cell growth, migration and invasion in vitro but also markedly inhibited the tumor growth, invasion, lymph node and lung metastasis in xenograft mice. Furthermore, Knockdown of IQGAP1 expression in ESCC cell lines led to a reversion of epithelial to mesenchymal transition (EMT) progress. These results suggest that IQGAP1 plays crucial roles in regulating ESCC occurrence and progression. IQGAP1 silencing may therefore develop into a promising novel anticancer therapy.
Bibliography:Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: XXW XZL. Performed the experiments: XXW KW XZL YZ. Analyzed the data: XXW KW XZL LQZ CXQ ZRL LWJ. Contributed reagents/materials/analysis tools: XXW HZW QJA XHW. Wrote the paper: XXW.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0096501